Retinol X - AOP Orphan Pharmaceuticals AG/Orphanix
Alternative Names: Retinol(X)Latest Information Update: 16 Oct 2022
At a glance
- Originator Orphanix
- Developer AOP Orphan Pharmaceuticals AG; Orphanix
- Class Retinoids; Vitamins
- Mechanism of Action Vitamin A replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Bronchopulmonary dysplasia
Most Recent Events
- 16 Oct 2022 Retinol X is still in phase II trials for Bronchopulmonary dysplasia in Australia (Orphanix pipeline, October 2022)
- 06 May 2020 Phase-II clinical trials in Bronchopulmonary dysplasia (Prevention) in Austria (IM), prior to May 2020 (AOP Orphan Pharmaceuticals AG pipeline, May 2020)
- 06 May 2020 Phase-II clinical trials in Bronchopulmonary dysplasia (Prevention) in Austria (IV), prior to May 2020 (AOP Orphan Pharmaceuticals AG pipeline, May 2020)